AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

Sanofi’s (NASDAQ:SNY) multiple sclerosis (MS) drug candidate tolebrutinib did not meet the primary endpoint of two studies testing the drug against relapsing MS. The drug did not significantly reduce ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine ...

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of the disease can progress more quickly or have a higher severity. Still, ...